Identification of a novel chromosome region, 13q21.33-q22.2, for susceptibility genes in familial chronic lymphocytic leukemia

Blood

Volumn 109, Issue 3, 2007, Pages 916-925

  Ng, David ^a   Toure, Ousmane ^a   Wei, Ming Hui ^a,b   Arthur, Diane C ^a   Abbasi, Fatima ^c   Fontaine, Laura ^d   Marti, Gerald E ^c   Fraumeni, Joseph F ^a   Goldin, Lynn R ^a   Caporaso, Neil ^a   Toro, Jorge R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^d WESTAT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CANCER PATIENT; CANCER RISK; CANCER SUSCEPTIBILITY; CHROMOSOME 13Q; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; DNA SEQUENCE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; GENE EXPRESSION; GENE IDENTIFICATION; GENE MAPPING; GENE MUTATION; GENETIC RISK; GENETIC SCREENING; GENETIC SUSCEPTIBILITY; GENOME ANALYSIS; HAPLOTYPE; HUMAN; INTERPHASE; LYMPHOCYTOSIS; MALE; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

EID: 33846885193     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2006-03-011825     Document Type: Article

References (53)

1. Ries LAG, Eisner MP, Kosary CL, et al, eds. SEER Cancer Statistics Review, 1975-2000. Bethesda, MD: National Cancer Institute; 2003.
2. Fitchett M, Griffiths MJ, Oscier DG, Johnson S, Seabright M. Chromosome abnormalities involving band 13q14 in hematologic malignancies. Cancer Genet Cytogenet. 1987;24:143-150.
3. Liu Y, Szekely L, Grander D, et al. Chronic lymphocytic leukemia cells with allelic deletions at 13q14 commonly have one intact RB1 gene: evidence for a role of an adjacent locus. Proc Natl Acad Sci U S A. 1993;90:8697-8701.
4. Hawthorn LA, Chapman R, Oscier D, Cowell JK. The consistent 13q14 translocation breakpoint seen in chronic B-cell leukaemia (BCLL) involves deletion of the D13S25 locus which lies distal to the retinoblastoma predisposition gene. Oncogene. 1993;8:1415-1419.
5. Brown AG, Ross FM, Dunne EM, Steel CM, Weir-Thompson EM. Evidence for a new tumor suppressor (DBM) in human B-cell neoplasia telomeric to the retinoblastoma gene. Nat Genet. 1993;3:67-72.
6. Kitamura E, Su G, Sossey-Alaoui K, et al. A transcription map of the minimally deleted region from 13q14 in B-cell chronic lymphocytic leukemia as defined by large scale sequencing of the 650 kb critical region. Oncogene. 2000;19:5772-5780.
7. Corcoran MM, Rasool O, Liu Y, et al. Detailed molecular delineation of 13q14.3 loss in B-cell chronic lymphocytic leukemia. Blood. 1998;91:1382-1390.
8. Bullrich F, Fujii H, Calin G, et al. Characterization of the 13q14 tumor suppressor locus in CLL: identification of ALT1, an alternative splice variant of the LEU2 gene. Cancer Res. 2001;61:6640-6648.
9. Bouyge-Moreau I, Rondeau G, Avet-Loiseau H, et al. Construction of a 780-kb PAC, BAC, and cosmid contig encompassing the minimal critical deletion involved in B cell chronic lymphocytic leukemia at 13q14.3. Genomics. 1997;46:183-190.
10. Dohner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910-1916.
11. Liu Y, Hermanson M, Grander D, et al. 13q deletions in lymphoid malignancies. Blood 1995;86:1911-1915.
12. Stilgenbauer S, Nickolenko J, Wilhelm J, et al. Expressed sequences as candidates for a novel tumor suppressor gene at band 13q14 in B-cell chronic lymphocytic leukemia and mantle cell lymphoma. Oncogene 1998;16:1891-1897.
13. Calin GA, Dumitru CD, Shimizu M, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2002;99:15524-15529.
14. Calin GA, Trapasso F, Shimizu M, et al. Familial cancer associated with a polymorphism in ARLTS1. N Engl J Med. 2005;352:1667-1676.
15. Capalbo S, Callea V, Musolino C, et al. Familial B-cell chronic lymphocytic leukemia in a population of patients from Southern Italy. Int J Hematol. 2004;79:354-357.
16. Goldin LR, Pfeiffer RM, Li X, Hemminki K. Familial risk of lymphoproliferative tumors in families of patients with chronic lymphocytic leukemia: results from the Swedish Family-Cancer Database. Blood. 2004;104:1850-1854.
17. Caporaso N, Marti GE, Goldin L. Perspectives on familial chronic lymphocytic leukemia: genes and the environment. Semin Hematol. 2004;42:201-206.
18. Marti GE, Carter C, Abbasi F, et al. B-cell monoclonal lymphocytosis and B-cell abnormalities in the setting of familial B-cell chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2003;52:1-12.
19. Goldin LR, Ishibe N, Sgambati M, et al. A genome scan of 18 families with chronic lymphocytic leukaemia. Br J Haematol. 2003;121:866-873.
20. Ishibe N, Sgambati MT, Fontaine L, et al. Clinical characteristics of familial B-CLL in the National Cancer Institute Familial Registry. Leuk Lymph. 2001;42:99-108.
21. University of California, Santa Cruz. BLAT: Blast-Like Alignment Tool. Available at: http://genome.ucsc.edu/cgi-bin/hgBlat. Accessed December 5, 2006.
22. Toro JR, Nickerson ML, Wei MH, et al. Mutations in the fumarate hydratase gene cause hereditary leiomyomatosis and renal cell cancer in families in North America. Am J Hum Genet. 2003;73:95-106.
23. ABI: Guide to performing relative quantitation of gene expression using real-time quantitative PCR. Tutorial, part no. 4371095. Foster City, CA: PE Applied Biosystems; 2004.
24. National Center for Biotechnology Information. Basic Local Alignment Search Tool (BLAST). http://www.ncbi.nlm.nih.gov/blast/. Accessed December 5, 2006.
25. Carter PH, Resto-Ruiz S, Washington GC, et al. Whole blood lysis: a flow cytometric analysis of three anticoagulants and five cell preparations. Cytometry. 1992;13:68-74.
26. Duque RE, Andreef M, Braylan RC, Diamond LW, Peiper SC. Consensus review of the clinical utility of DNA flow cytometry in neoplastic hematopathology. Cytometry. 1993;14:492-496.
27. Fleisher TA, Marti GE. Detection of unseparated human lymphocytes by flow cytometry. In: Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W, eds. Current Protocols in Immunology. Vol 1. New York, NY: John Wiley and Sons; 1991:7.9.1-7.9.7.
28. Kamihara S, Matutes E, Marco JG, et al. Flow cytometry detection of minimal DNA aneuploidy in mature lymphoid leukemias: comparison with metaphase and interphase cytogenetics. Int J Oncol. 1994;5:211-214.
29. Zenger ZE, Vogt R, Mandy F, Schwartz A, Marti GE. Quantitative flow cytometry: inter-laboratory variation. Cytometry. 1998;33:138-145.
30. Nicholson JKA, Rao PE, Calvelli T, et al. Artifactual staining of monoclonal antibodies in twocolor combinations is due to an immunoglobulin in the serum and plasma. Cytometry. 1994;18:140-146.
31. Shankey TV, Rabinovitch PS, Bagwell B, et al. Guidelines for implementation of clinical DNA cytometry: International Society for Analytical Cytology. Cytometry. 1993;14:472-477.
32. University of California Santa Cruz. Genome Bioinformatics. http://genome.ucsc.edu/. Accessed December 5, 2006.
33. European Bioinformatics Institute and Wellcome Trust Sanger Institute. Ensembl Genome Browser. http://www.ensembl.org. Accessed December 5, 2006.
34. Wellcome Trust Sanger Institute. miRBase::Sequences. http://microrna. sanger-.ac.uk/sequences/. Accessed December 5, 2006.
35. Rozenblum E, Vahteristo P, Sandberg T, et al. A genomic map of a 6-Mb region at 13q21-q22 implicated in cancer development: identification and characterization of candidate genes. Hum Genet. 2002;110:111-121.
36. Rawstron AC, Yuille MR, Fuller J, et al. Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion. Blood. 2002;100:2289-2291.
37. Larramendy ML, Kushnikova T, Bjorkvist AM, et al. Comparative genomic hybridization reveals complex genetic changes in primary breast cancer tumors and their cell lines. Cancer Genet Cytogenet. 2000;119:132-138.
38. Kainu T, Juo SH, Desper R, et al. Somatic deletions in hereditary breast cancers implicate 13q21 as a putative novel breast cancer susceptibility locus. Proc Natl Acad Sci U S A. 2000;97:9603-9608.
39. Dong JT, Chen C, Stultz BG, Isaacs JT, Frierson HF Jr. Deletion at 13q21 is associated with aggressive prostate cancers. Cancer Res. 2000;60:3880-3883.
40. Gray SG, Kytola S, Matsunaga T, Larsson C, Ekstrom TJ. Comparative genomic hybridization reveals population-based genetic alterations in hepatoblastomas. Br J Cancer. 2000;83:1020-1025.
41. Szekeres-Bartho J, Kilar F, Falkay G, et al. The mechanism of the inhibitory effect of progesterone on lymphocyte cytotoxicity, I: progesterone-treated lymphocytes release a substance inhibiting cytotoxicity and prostaglandin synthesis. Am J Reprod Immunol Microbiol. 1985;9:19-22.
42. Lachmann M, Gelbmann D, Kalman E, et al. PIBF (progesterone induced blocking factor) is overexpressed in highly proliferating cells and associated with the centrosome. Int J Cancer. 2004;112:51-60.
43. Salisbury JL, Whitehead CM, Lingle WL, Barrett SL. Centrosomes and cancer. Biol Cell. 1999;91:451-460.
44. Nagase T, Ishikawa K, Suyama M, et al. Prediction of the coding sequences of unidentified human genes, XIII: the complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro. DNA Res. 1999;6:63-70.
45. Wu K, Yang Y, Wang C, et al. DACH1 inhibits transforming growth factor-beta signaling through binding Smad4. J Biol Chem. 2003;278:51673-51684.
46. Chen C, Bhalala HV, Vessella RL, Dong JT. KLF5 is frequently deleted and down-regulated but rarely mutated in prostate cancer. Prostate. 2003;55:81-88.
47. Chen C, Bhalala HV, Qiao H, Dong JT. A possible tumor suppressor role of the KLF5 transcription factor in human breast cancer. Oncogene. 2002;21:6567-6572.
48. Imhof A, Schuierer M, Werner O, et al. Transcriptional regulation of the AP-2alpha promoter by BTEB-1 and AP-2rep, a novel wt-1/egr-related zinc finger repressor. Mol Cell Biol. 1999;19:194-204.
49. Pellikainen J, Kataja V, Ropponen K, et al. Reduced nuclear expression of transcription factor AP-2 associates with aggressive breast cancer. Clin Cancer Res. 2002;8:3487-3495.
50. Slater H, Shaw JH, Dawson G, et al. Maternal uniparental disomy 13 in a phenotypically normal child. J Med Genet. 1994;31:644-646.
51. Berend SA, Feldman GL, McCaskill C, et al. Investigation of two cases of of paternal disomy 13 suggests timing of isochromosome formation and mechanisms leading to uniparental disomy. Am J Med Genet. 1999;82:275-281.
52. Soler A, Margarit E, Queralt R, et al. Paternal isodisomy 13 in a normal newborn infant after trisomy rescue evidenced by prenatal diagnosis. Am J Med Genet. 2000;90:291-293.
53. Sellick GS, Webb EL, Allinson R, et al. A high-density SNP genomewide linkage scan for chronic lymphocytic leukemia-susceptibility loci. Am J Hum Genet. 2005;77:420-429.